Hemagen Diagnostics Research and Development Expenses 2010-2012 | HMGN

Hemagen Diagnostics research and development expenses from 2010 to 2012. Research and development expenses can be defined as an expense arising from studies and product development processes.

Hemagen Diagnostics Research and Development Expenses 2010-2012 | HMGN

Hemagen Diagnostics research and development expenses from 2010 to 2012. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$227.2B
Boston Scientific (BSX)$140.7B
Stryker (SYK)$132.3B
EssilorLuxottica (ESLOY)$128.4B
Medtronic (MDT)$105.9B
Lonza Group Ag (LZAGY)$47.4B
Haleon (HLN)$46.2B
ResMed (RMD)$31.3B
Agilent Technologies (A)$29.2B
GE HealthCare Technologies (GEHC)$28.6B
Terumo (TRUMY)$28.2B
Koninklijke Philips (PHG)$22.2B
Zimmer Biomet Holdings (ZBH)$19.4B
Insulet (PODD)$17.3B
Baxter (BAX)$14.8B
Smith & Nephew SNATS (SNN)$11.4B
Sunny Optical Technology (SNPTF)$7.6B
Lantheus Holdings (LNTH)$6.9B
Bio-Rad Laboratories (BIO)$6.7B
Demant (WILYY)$6.6B
Prestige Consumer Healthcare (PBH)$4B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Perrigo (PRGO)$3.5B
ICU Medical (ICUI)$3.4B
Haemonetics (HAE)$2.9B
Envista Holdings (NVST)$2.6B
GN Store Nord (GNNDY)$2.2B
LeMaitre Vascular (LMAT)$1.9B
QuidelOrtho (QDEL)$1.7B
AtriCure (ATRC)$1.6B